Pluri Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Pluri Inc. (PLUR) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$25.37 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-09-10
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$6.19M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$6.17M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$6.87M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$6.13M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2026 was -$25.37M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$23.25M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$21.34M.
- Pluri Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$28.89M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | -$12.37M derived: sum of 2 quarters · filed 2026-09-10 | -$19.24M derived: sum of 3 quarters · filed 2026-09-10 | -$25.37M 10-K · filed 2026-09-10 | |||
| 2026-03-31 | -$6.17M 10-Q · filed 2026-05-14 | -$13.04M derived: sum of 2 quarters · filed 2026-05-14 | -$19.18M 10-Q · filed 2026-05-14 | -$26.95M derived: sum of 4 quarters · filed 2026-09-10 | |||
| 2025-12-31 | -$6.87M 10-Q · filed 2026-02-12 | -$13.00M 10-Q · filed 2026-02-12 | -$20.77M derived: sum of 3 quarters · filed 2026-09-10 | -$27.11M derived: sum of 4 quarters · filed 2026-09-10 | |||
| 2025-09-30 | -$6.13M 10-Q · filed 2025-11-12 | -$13.90M derived: sum of 2 quarters · filed 2026-09-10 | -$20.24M derived: sum of 3 quarters · filed 2026-09-10 | -$23.35M derived: sum of 4 quarters · filed 2026-09-10 | |||
| 2025-06-30 | -$7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | -$14.10M derived: sum of 2 quarters · filed 2026-09-10 | -$17.21M derived: sum of 3 quarters · filed 2026-09-10 | -$23.25M 10-K · filed 2026-09-10 | |||
| 2025-03-31 | -$6.33M 10-Q · filed 2026-05-14 | -$9.45M derived: sum of 2 quarters · filed 2026-05-14 | -$15.48M 10-Q · filed 2026-05-14 | -$21.34M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$3.11M 10-Q · filed 2026-02-12 | -$9.15M 10-Q · filed 2026-02-12 | -$15.01M derived: sum of 3 quarters · filed 2026-02-12 | -$20.40M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-09-30 | -$6.04M 10-Q · filed 2025-11-12 | -$11.90M derived: sum of 2 quarters · filed 2025-11-12 | -$17.29M derived: sum of 3 quarters · filed 2025-11-12 | -$22.28M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | -$11.25M derived: sum of 2 quarters · filed 2025-09-17 | -$16.25M derived: sum of 3 quarters · filed 2025-09-17 | -$21.34M 10-K · filed 2025-09-17 | |||
| 2024-03-31 | -$5.39M 10-Q · filed 2025-05-13 | -$10.38M derived: sum of 2 quarters · filed 2025-05-13 | -$15.48M 10-Q · filed 2025-05-13 | -$22.09M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | -$4.99M 10-Q · filed 2025-02-11 | -$10.09M 10-Q · filed 2025-02-11 | -$16.70M derived: sum of 3 quarters · filed 2025-02-11 | -$24.46M derived: sum of 4 quarters · filed 2025-02-11 | |||
| 2023-09-30 | -$5.10M 10-Q · filed 2024-11-12 | -$11.70M derived: sum of 2 quarters · filed 2024-11-12 | -$19.46M derived: sum of 3 quarters · filed 2024-11-12 | -$27.72M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | -$14.36M derived: sum of 2 quarters · filed 2024-09-18 | -$22.62M derived: sum of 3 quarters · filed 2024-09-18 | -$28.89M 10-K · filed 2024-09-18 | |||
| 2023-03-31 | -$7.76M 10-Q · filed 2024-05-09 | -$16.01M derived: sum of 2 quarters · filed 2024-05-09 | -$22.28M 10-Q · filed 2024-05-09 | -$31.36M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$8.25M 10-Q · filed 2024-02-12 | -$14.52M 10-Q · filed 2024-02-12 | -$23.61M derived: sum of 3 quarters · filed 2024-02-12 | -$33.52M derived: sum of 4 quarters · filed 2024-02-12 | |||
| 2022-09-30 | -$6.27M 10-Q · filed 2023-11-13 | -$15.35M derived: sum of 2 quarters · filed 2023-11-13 | -$25.27M derived: sum of 3 quarters · filed 2023-11-13 | -$36.21M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | -$19.00M derived: sum of 2 quarters · filed 2023-09-12 | -$29.94M derived: sum of 3 quarters · filed 2023-09-12 | -$41.37M 10-K · filed 2023-09-12 | |||
| 2022-03-31 | -$9.92M 10-Q · filed 2023-05-09 | -$20.86M derived: sum of 2 quarters · filed 2023-05-09 | -$32.29M 10-Q · filed 2023-05-09 | -$46.86M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$10.94M 10-Q · filed 2023-02-13 | -$22.37M 10-Q · filed 2023-02-13 | $22.37M 10-Q · filed 2022-02-07 | -$36.94M derived: sum of 3 quarters · filed 2023-02-13 | -$51.19M derived: sum of 4 quarters · filed 2023-02-13 | ||
| 2021-09-30 | -$11.43M 10-Q · filed 2022-11-10 | $11.43M 10-Q · filed 2021-11-08 | -$26.00M derived: sum of 2 quarters · filed 2022-11-10 | -$40.25M derived: sum of 3 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-21 | -$28.82M derived: sum of 2 quarters · filed 2022-09-21 | -$49.87M 10-K · filed 2022-09-21 | $49.87M 10-K · filed 2021-09-13 | |||
| 2021-03-31 | -$14.25M 10-Q · filed 2022-05-09 | -$35.30M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |